A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person.
"Although Niklas has worked for Diamyd for a relatively short period, he has left a mark on the organization. I want to express gratitude on behalf of the company - especially regarding the role he played in our most recent fund raising - and wish him success in his continued career," says Anders Essen-Möller, CEO of Diamyd Medical.
About Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The Company has established a facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.